

## Investigational Trials of CC-99282 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Non-Hodgkin Lymphoma

CC-99282-NHL-001


A Phase 1, Multi-Center, Open-Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL)<sup>1</sup>

CURRENTLY ENROLLING ACROSS THE US, CANADA, AND EUROPE NCT03930953 Phase 1 Pharmacokinetics, objective response rate (ORR), time to response, duration of response (DoR), Dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and adverse events (AEs) progression-free survival (PFS), and overall survival (OS) KEY ELIGIBILITY CRITERIA TREATMENT\* Estimated N=100 FOLLOW-UP Part A: Dose Escalation Part B: Dose Expansion CC-99282 monotherapy R/R DLBCL R/R NHL ECOG PS ≤2 ANC ≥1.5 x 109/L without growth factor support for CC-99282 monotherapy 7 days (14 days if pegfilgrastim) CC-99282 monotherapy Follow-up for safety Hemoglobin ≥8 g/dL Assessment for overall (within 28 days after last dose) Platelets ≥75 x 109/L without transfusion for 7 days safety and tolerability AST/ALT ≤2.5 x ULN CC-99282 + rituximab Serum bilirubin <1.5 x ULN R/R DLBCL CrCl ≥60 mL/min CC-99282 + rituximab R/R FL \*Treatment for a maximum of 2 years.

CONTACT: ClinicalTrialDisclosure@bms.com

CC-99282-CLL-001

A Phase 1B, Multicenter, Open-Label Study to Determine the Safety,
Pharmacokinetics, and Preliminary Efficacy of CC-99282 in Combination
With Obinutuzumab in Subjects With Relapsed or Refractory Chronic
Lymphocytic Leukemia/Small Lymphocytic Lymphoma<sup>2</sup>



CONTACT: ClinicalTrialDisclosure@bms.com

The safety and efficacy of CC-99282 and/or its uses are under investigation and have not been established.

There is no guarantee that CC-99282 will receive health authority approval or become commercially available in any country for the uses being investigated.